- Cohance Lifesciences has appointed Umang Vohra as Executive Chairman effective May 1, 2026, and Group CEO effective May 20, 2026.
- Vivek Sharma will step down as Executive Chairman and continue as an advisor for nine months to support the transition.
Cohance Lifesciences Limited has appointed Umang Vohra as Executive Chairman, effective May 1, 2026, and Group CEO, effective May 20, 2026, as part of a leadership transition aimed at supporting its next phase of growth. Vohra succeeds Vivek Sharma, who is stepping down from the Executive Chairman role for personal reasons and will remain with the company as an advisor for nine months.
The appointment was made by the Board as a strategic decision to align leadership with the company’s transformation priorities. Cohance operates as an integrated CDMO platform focused on complex chemistry, antibody-drug conjugates (ADCs), oligonucleotides, and advanced API development, with capabilities spanning contract manufacturing, process R&D, and specialty materials.
Vohra brings more than three decades of experience in the pharmaceutical industry. Most recently, he served as CEO and Managing Director of Cipla Limited, where he led the company’s transformation into a diversified global pharmaceutical business. His experience includes managing large-scale operations with a focus on customers, quality, and operational execution.
“I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform.” He added that the company’s technology capabilities, R&D strength, and leadership team provide a strong foundation for future growth.
Umang Vohra
Cohance stated that its platform is supported by integrated R&D centers and more than 400 scientists, with established partnerships across global pharmaceutical companies. The leadership transition is intended to build on this foundation and support the company’s continued expansion in CDMO and contract manufacturing services.
